Financial Performance - Operating revenue for the period reached CNY 3,917,473,124.25, a 58.88% increase compared to the same period last year[10] - Net profit attributable to shareholders surged by 190.40% to CNY 643,789,273.74[10] - Basic earnings per share rose by 160.87% to CNY 0.60[10] - The company reported a net profit of CNY 1,477,586,003.68 for the year-to-date, reflecting a 389.75% increase compared to the same period last year[10] - Operating revenue rose by 66.43% to CNY 8,620,752,350.59 from CNY 5,179,810,282.95, driven by rising pig prices and increased sales in corn storage and feed business[28] - Net profit attributable to the parent company surged by 389.75% to CNY 1,477,586,003.68 from CNY 301,704,024.67, influenced by higher profitability in pharmaceutical products and feed business[31] - The total comprehensive income for the period reached ¥1,514,841,362.12, compared to ¥232,156,798.82 in the previous period[104] - The net profit attributable to the parent company was ¥1,477,586,003.68, an increase from ¥301,704,024.67 year-over-year[104] Assets and Liabilities - Total assets increased by 8.26% to CNY 12,075,369,583.87 compared to the end of the previous year[10] - The company’s cash and cash equivalents increased by 36.20% to CNY 2,725,948,476.64 from CNY 2,001,458,308.06 due to expanded asset scale and improved sales recovery in corn storage and oil business[28] - Total liabilities decreased to approximately ¥5.47 billion, down 8.6% from ¥5.99 billion[77] - Total assets reached approximately ¥12.08 billion, an increase of 8.2% from ¥11.15 billion[75] - Total liabilities reached approximately ¥5.99 billion, with current liabilities at ¥4.30 billion and non-current liabilities at ¥1.69 billion[132] Cash Flow - Cash flow from operating activities increased slightly by 0.29% to CNY 874,523,500.90[10] - The net cash flow from operating activities increased by 48.33% to CNY 2,097,715,885.13 from CNY 1,414,261,767.27, attributed to better cash recovery from sales[31] - The net cash flow from operating activities was ¥8,286,840,440.93, compared to ¥5,048,448,839.95 in the previous period, showing a growth of approximately 63.4%[114] - The total cash outflow from operating activities amounted to 6,189,124,555.80 CNY, up from 3,634,187,072.68 CNY, indicating a significant increase in operational expenses[116] Research and Development - Research and development expenses increased by 74.97% to CNY 102,620,466.88 from CNY 58,650,940.05, reflecting a higher investment in R&D activities[31] - Research and development expenses increased to ¥44,347,580.79 from ¥10,252,871.00, representing a rise of 333.5% year-over-year[88] - Research and development expenses increased to ¥32,054,894.16, compared to ¥14,014,921.70, marking a growth of 128.7%[93] Shareholder Equity - Net assets attributable to shareholders increased by 30.22% to CNY 5,980,766,651.11 year-on-year[10] - Shareholders' equity increased to approximately ¥6.60 billion, up 27.8% from ¥5.16 billion[79] - The company's equity totaled approximately ¥5.16 billion, with total equity attributable to shareholders at approximately ¥4.59 billion[132] Investment and Financing - The company raised a total of RMB 1,000,000,000.00 from the issuance of 10 million convertible bonds, with a net amount of RMB 981,550,400.00 after deducting fees[60] - The company reported a derivative investment amount of RMB 1,890,500.00, with a year-end net asset ratio of 0.11%[38] - The company has a long-term loan of approximately $1.31 billion and bonds payable of about $184 million[137] Operational Efficiency - The company’s management expenses increased by 63.33% to CNY 406,209,311.65 from CNY 248,697,195.18, driven by expanded operations and increased personnel costs[31] - The company reported a financial expense of ¥2,683,981.61, a decrease from ¥16,893,187.34, indicating a reduction of 84.1%[93] Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[76] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[87] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[100]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥4,703,279,226.34, representing a 73.29% increase compared to ¥2,714,170,240.43 in the same period last year[23]. - The net profit attributable to shareholders of the listed company reached ¥833,796,729.94, a significant increase of 942.09% from ¥80,011,586.86 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥856,324,136.19, up 1,063.01% from ¥73,630,128.00 in the same period last year[23]. - The net cash flow from operating activities was ¥1,223,192,384.23, an increase of 125.58% compared to ¥542,238,516.56 in the previous year[23]. - Basic earnings per share increased to ¥0.78, up 875.00% from ¥0.08 in the same period last year[23]. - The diluted earnings per share was ¥0.77, reflecting an increase of 862.50% from ¥0.08 in the previous year[23]. - The weighted average return on equity rose to 16.64%, up 14.21% from 2.43% in the previous year[23]. - The company achieved total revenue of CNY 4,703.28 million, a year-on-year increase of 73.29%[47]. - The net profit attributable to shareholders reached CNY 833.80 million, up 942.09% compared to the previous year[47]. Business Segments - The feed business generated sales revenue of CNY 1,936.17 million, an increase of 47.89% year-on-year, with sales volume growing by 29.52% to 803,000 tons[47]. - The company's pig farming business reported sales revenue of CNY 1,279.91 million, a significant increase of 167.05% year-on-year, with pig output rising by 4.22% to 425,100 heads[48]. - The pharmaceutical business saw sales revenue of CNY 360.36 million, reflecting a year-on-year growth of 39.75% due to increased government subsidies and higher vaccine prices[48]. - The revenue from the food farming sector surged by 167.05% to ¥1,279,909,931.87, up from ¥479,272,667.52, reflecting a substantial increase in pig prices[58]. - The corn storage business revenue increased by 184.24% to ¥410,397,105.73 from ¥144,383,232.32, showcasing strong market demand[58]. Assets and Investments - Total assets at the end of the reporting period were ¥11,106,418,614.82, a slight decrease of 0.43% from ¥11,154,464,066.40 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company increased by 15.17% to ¥5,289,743,746.19 from ¥4,592,802,200.06 at the end of the previous year[23]. - Long-term equity investments increased by 2.39% compared to the end of the previous year, primarily due to changes in investments in associated companies[40]. - Fixed assets grew by 5.20% year-on-year, mainly due to the completion of construction projects such as the 200,000-head fattening farm[40]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,977,325,644, accounting for 17.80% of total assets, a decrease of 5.48% compared to the previous year[66]. - Inventory increased to ¥3,060,637,870, representing 27.56% of total assets, an increase of 4.46% year-on-year due to expanded operational scale[66]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company reported a significant increase in sales expenses, which rose by 21.15% to ¥216,844,994.81 due to business expansion and changes in transportation methods[54]. - The company's financial expenses increased by 13.14% to ¥94,409,030.40, attributed to increased bank loans for business expansion[54]. - The net increase in cash and cash equivalents was negative at -¥17,881,296.64, a decline of 138.36% compared to an increase of ¥46,613,925.35 in the previous year, mainly due to reduced cash flow from financing activities[54]. Project Investments - The company has cumulative raised funds of ¥981,550,400, with ¥56,951,260 already utilized by June 30, 2020[80]. - The company has decided to terminate the "High-tech Zone North Pharmaceutical Industrial Park Phase II Project" to focus on other projects due to changes in market conditions and strategic needs[84]. - The company aims to improve the efficiency of fund usage and accelerate project implementation to gain market share and competitive advantage[84]. - The "Animal Biosecurity Level 3 Upgrade Project" has a total committed investment of CNY 167.22 million, with CNY 31.58 million invested, achieving 50.56% progress[81]. - The "Gansu Yongchang Pig Farm Phase I Project" has a total committed investment of CNY 90 million, with CNY 15.75 million invested, achieving 80.08% progress[81]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 55,685[186]. - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., held 26.44% of shares, totaling 283,929,184 shares[191]. - The total shares held by the top ten unrestricted common shareholders amounted to 1,000,000,000 shares[191]. - The company did not experience any changes in its controlling shareholder during the reporting period[195]. - The company reported no preferred shares in the reporting period[199]. Compliance and Governance - The company has maintained its independence and compliance with relevant laws and regulations throughout the reporting period[119]. - The company has not undergone any bankruptcy restructuring during the reporting period[128]. - There were no significant litigation or arbitration matters during the reporting period[128]. - The company has implemented an employee stock ownership plan, approved in meetings held on May 29 and June 15, 2020[132]. - The half-year financial report has not been audited[125].

Financial Performance - The company's operating revenue for Q1 2020 was ¥1,983,537,035.47, representing a 64.63% increase compared to ¥1,204,813,855.90 in the same period last year[10] - Net profit attributable to shareholders was ¥334,552,715.62, a significant increase of 1,056.82% from ¥28,920,108.83 in the previous year[10] - Basic earnings per share were ¥0.31, up 933.33% from ¥0.03 in the same period last year[10] - The net profit attributable to the parent company reached CNY 334.55 million, reflecting a year-on-year growth of 1056.82%, driven by a significant increase in pork prices in the national market[23] - Net profit for Q1 2020 reached CNY 325,628,705.24, compared to a mere CNY 24,117.73 in Q1 2019, indicating a substantial improvement in profitability[69] - Total comprehensive income attributable to the parent company is ¥334,552,715.62, up from ¥28,920,108.83, showing a remarkable increase[72] Cash Flow - The net cash flow from operating activities reached ¥510,611,919.66, marking a 421.58% increase from ¥97,896,377.87 in the same period last year[10] - The net cash flow from operating activities was 307,431,927.32, a significant improvement compared to -9,605,854.12 from the previous period[87] - Cash inflow from operating activities totaled 382,316,072.17, down 22.6% from 494,327,854.80 in the prior period[87] - The net cash flow from investing activities was 23,041,892.88, a recovery from -315,436,767.52 in the prior period[90] - The company reported a cash increase of 283,220,985.13 during the period, compared to 174,908,275.25 in the previous period[86] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,609,154,321.49, an increase of 4.08% from ¥11,154,464,066.40 at the end of the previous year[10] - The total liabilities of the company reached CNY 6.09 billion, compared to CNY 5.99 billion, marking an increase of approximately 1.67%[51][54] - Total liabilities amounted to CNY 5,989,645,710.31, with current liabilities at CNY 4,300,955,352.67 and non-current liabilities at CNY 1,688,690,357.64[97] - The company's total equity was CNY 5,164,818,356.09, with equity attributable to shareholders of the parent company at CNY 4,592,802,200.06[97] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 65,925[14] - The largest shareholder, Xinjiang Production and Construction Corps, held 26.58% of the shares[14] Research and Development - Research and development expenses increased by 74.47% year-on-year to CNY 22.02 million, indicating a stronger focus on R&D investment[22] - Research and development expenses for Q1 2020 were CNY 22,020,019.72, compared to CNY 12,620,993.58 in the previous year, highlighting an increased focus on innovation[66] - Research and development expenses increased significantly to ¥18,139,174.00, up from ¥10,086,016.17, marking an increase of about 80.2%[73] Financial Management - The company's financial expenses increased by 30.09% year-on-year to CNY 55.08 million, primarily due to a rise in loan balances[22] - The company incurred financial expenses of ¥15,000,078.63, down from ¥16,753,346.01, which is a decrease of approximately 10.5%[73] Operational Highlights - The company's operating revenue for the reporting period was CNY 1,983.54 million, an increase of 64.63% year-on-year, primarily due to higher sales prices in the food farming business and expanded sales in the feed business[22] - Total operating costs for Q1 2020 were CNY 1,619,680,424.18, up from CNY 1,184,475,340.91, reflecting a significant increase in operating expenses[66] - The company reported a gross profit margin improvement, with gross profit for Q1 2020 at CNY 613,856,611.29, compared to CNY 219,281,515.99 in Q1 2019[66] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[60] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[102]

Financial Performance - By the end of 2023, the company plans to achieve feed production and sales of 3 million tons, with a sales revenue of 9 billion RMB[6]. - The company aims to have a breeding stock of 200,000 to 250,000 sows and an annual output of 4 million pigs, generating sales revenue of 10 billion RMB by 2023[7]. - The biopharmaceutical business is projected to achieve sales revenue of 2 billion RMB by 2023, positioning the company among the top three in the domestic animal health industry and top ten globally[10]. - The company plans to process 1 million tons of cottonseed, generating 2.5 billion RMB in revenue by 2023, aiming to become the leading brand in high-protein cotton meal[10]. - The corn storage and sales business targets 3 million tons with a revenue of 6.5 billion RMB by 2023, focusing on high-quality grain supply in the Northwest region[10]. - The company's operating revenue for 2019 was ¥7,476,316,392.02, representing a 41.78% increase compared to ¥5,273,032,350.33 in 2018[33]. - The net profit attributable to shareholders for 2019 was ¥644,486,713.22, which is a 105.43% increase from ¥313,726,252.74 in 2018[33]. - The net cash flow from operating activities improved to ¥306,979,542.98 in 2019, a significant recovery from a negative cash flow of ¥1,178,441,646.71 in 2018, marking a 126.05% increase[33]. - Basic earnings per share for 2019 rose to ¥0.60, an 81.82% increase from ¥0.33 in 2018[33]. - Total assets at the end of 2019 were ¥11,154,464,066.40, up 31.09% from ¥8,508,742,207.44 at the end of 2018[36]. - The net assets attributable to shareholders increased by 43.10% to ¥4,592,802,200.06 at the end of 2019, compared to ¥3,209,604,751.62 at the end of 2018[36]. - The company reported a quarterly revenue of ¥2,465,640,042.52 in Q3 2019, which was the highest quarterly revenue for the year[39]. - The company received government subsidies amounting to ¥17,195,351.30 in 2019, slightly down from ¥19,967,775.21 in 2018[40]. - The company achieved total operating revenue of CNY 747,631.64 million, a year-on-year increase of 41.78%[63]. - Net profit attributable to shareholders reached CNY 64,448.67 million, reflecting a growth of 105.43% compared to the previous year[63]. - The feed business generated sales revenue of CNY 293,077.24 million, up 14.39% year-on-year, accounting for 39.20% of total revenue[63]. - The pharmaceutical business saw a decline in sales revenue to CNY 55,519.23 million, down 25.96% year-on-year, representing 7.43% of total revenue[64]. - Revenue from pig farming and food processing surged to CNY 164,412.01 million, a 92.34% increase year-on-year, making up 21.99% of total revenue[64]. - The company reported a comprehensive gross profit margin of 24.99%, an increase of 4.02 percentage points year-on-year[65]. Investment and Expansion - The company plans to invest in talent acquisition, information technology application, and compliance management to strengthen operational capabilities across business segments[11]. - The company expanded its consolidation scope by acquiring several agricultural companies in Xinjiang, enhancing its market presence[86]. - The company has made a significant equity investment of ¥14,922,300.00 in Xinjiang Tofeng Glacier Animal Husbandry Co., Ltd., acquiring a 35.48% stake[118]. - The ongoing major non-equity investment project, the upgrade of the veterinary biological safety level three protection project, has an actual investment of ¥122,678,020.95, with 66% project completion[119]. - The total investment amount for the reporting period was ¥1,354,728,203.71, representing a 126.26% increase compared to ¥598,741,419.38 in the same period last year[115]. - The company has initiated a biosecurity upgrade project with a planned investment of 16,722, and an actual investment of 5,296.64, achieving 31.67% of the planned investment[131]. - The company is focusing on expanding its pig farming operations in Gansu province to meet market demand due to the exit of smaller farmers[127]. - The company aims to enhance the efficiency of fund utilization to support its current development needs[127]. - The company has decided to terminate certain projects to better align with its strategic goals and improve investment efficiency[127]. - The company plans to construct a modern pig breeding farm in Xinjiang with a capacity of 10,000 parent pigs, divided into two phases of 4,800 pigs each[136]. - The total investment for the Xinjiang modern pig breeding farm project is approximately 1,475.68 million yuan, representing a 14.76% increase in project scale[138]. Research and Development - The company has a strong focus on R&D, with a recognized technology center and a commitment to enhancing innovation capabilities[63]. - The company is developing a dual inactivated vaccine for porcine circovirus type 2 and Mycoplasma pneumonia, which has shown high antigen expression and safety[95]. - The company has received approval for clinical trials of a new vaccine for foot-and-mouth disease, demonstrating effective immune response in trials[100]. - The company increased its R&D personnel from 203 to 388, a growth of 91.13% year-over-year[106]. - R&D investment amounted to ¥93,227,327.86 in 2019, representing a 5.71% increase from ¥88,192,934.83 in 2018[106]. - The company is developing a dual vaccine for small ruminant plague and goat pox, which is the first of its kind in China and internationally[102]. - The dual inactivated vaccine for small ruminant plague and goat pox is currently under registration, with safety improvements noted due to the use of cell culture for antigen production[103]. - The company plans to enhance its investment in disease prevention measures in response to the increasing demand for animal vaccines[151]. Market Trends and Challenges - The animal vaccine market in China is projected to grow from 242 billion CNY in 2018 to approximately 346 billion CNY by 2023, indicating a compound annual growth rate of about 8%-12%[150]. - The company anticipates that the commercialization of African swine fever vaccines will significantly boost the pig vaccine market, potentially doubling its scale[151]. - The feed industry is expected to see a significant increase in concentration, with a projected annual growth rate of 2.1%, reaching an industrial feed consumption of 28,053 million tons by 2029[155]. - The top three domestic pig farming companies hold market shares of 3.2%, 1.6%, and 0.8%, indicating substantial room for growth in market concentration[156]. - The company is focusing on expanding its market presence in the animal vaccine sector, driven by government policies promoting mandatory immunization[151]. - The company is responding to the African swine fever outbreak by expanding its scale and improving biosecurity measures, positioning itself to capture market share from exiting small and medium-sized farmers[134]. Corporate Governance and Compliance - The company committed to avoiding any business competition with its controlling shareholder, ensuring no similar business operations will be conducted post-transaction[177]. - The company guarantees that related party transactions will be minimized and conducted in compliance with legal regulations, ensuring no illegal occupation of funds or assets[177]. - The company has maintained a consistent cash dividend policy over the past three years, with dividends paid in 2017, 2018, and 2019[170]. - The company plans to distribute no less than 10% of its distributable profits as cash dividends annually over the next three years, with potential increases if net profits continue to grow[180]. - The company will actively pursue cash profit distribution in the next three years, adhering to relevant laws and regulations[180]. - The company has implemented new financial instrument accounting standards starting January 1, 2019, affecting the presentation of financial statements[184]. - The company did not experience any major accounting errors that required retrospective restatement during the reporting period[192]. - There were no significant lawsuits or arbitration matters reported during the period[198]. - The company did not face any situations that could lead to suspension or termination of its listing[197].

Financial Performance - Operating revenue for the reporting period was ¥2,465,640,042.52, representing a year-on-year increase of 73.06%[10] - Net profit attributable to shareholders was ¥221,692,437.81, up 46.57% from the same period last year[10] - Basic earnings per share increased to ¥0.23, reflecting a growth of 43.75% compared to the previous year[10] - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of ¥219,135,218.04, up 45.84% year-on-year[10] - Total operating revenue for Q3 2019 reached ¥2,465,640,042.52, a significant increase of 73.1% compared to ¥1,424,735,670.05 in the same period last year[61] - Net profit for Q3 2019 was ¥203,663,575.62, up 36.8% from ¥148,894,233.99 in Q3 2018[63] - The net profit attributable to the parent company was ¥301,704,024.67, an increase of 16.4% from ¥259,315,165.73 in the previous period[80] - The total comprehensive income attributable to the parent company increased to ¥301,704,024.67 from ¥259,315,165.73, a growth of 16.4%[84] Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,939,886,091.88, an increase of 5.07% compared to the end of the previous year[10] - Total current assets decreased to ¥4,969,829,014.21 from ¥5,857,658,521.18, a decline of approximately 15.1% year-over-year[44] - Total liabilities decreased to ¥4,605,194,844.18 from ¥5,229,930,251.35, a decline of about 11.9%[49] - The company's total liabilities increased to ¥3,442,452,421.37, compared to ¥3,118,704,637.60 in the previous year, reflecting a growth of 10.4%[60] - The company's total assets reached ¥6,519,472,692.73, up from ¥5,747,209,589.20, indicating a growth of 13.4% year-over-year[60] - Long-term borrowings increased to ¥1,871,000,000.00 from ¥600,000,000.00, marking an increase of approximately 211.8%[49] - The company reported a total equity of CNY 3,278,811,956.09, including CNY 1,441,418,870.28 in undistributed profits[112] Cash Flow - Net cash flow from operating activities surged to ¥872,023,250.70, a dramatic increase of 1,976.59% year-on-year[10] - Cash flow from operating activities increased to ¥4,929,708,187.66, up from ¥3,153,380,741.49 in the previous period, reflecting a growth of 56%[93] - The company recorded a net cash inflow from operating activities of ¥1,414,261,767.27, a significant increase compared to ¥79,249,874.10 in the previous period[93] - Operating cash inflow totaled ¥783,558,297.98, a significant increase from ¥339,305,350.78 in the previous period[102] - Net cash flow from operating activities was -¥118,542,553.63, improving from -¥707,852,803.03 year-over-year[102] Shareholder Information - The total number of shareholders at the end of the reporting period was 62,668[14] - The largest shareholder, Xinjiang Production and Construction Corps, held 28.04% of the shares, totaling 283,929,184 shares[14] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[19] Inventory and Receivables - Accounts receivable decreased by 47.72% to ¥36,974,095.93 due to normal payment of overdue accounts during the reporting period[23] - Inventory decreased by 44.62% to ¥1,385,429,172.83 attributed to seasonal sales in the agricultural products business[23] - Accounts receivable increased significantly to ¥602,930,018.54 from ¥215,224,695.75, representing an increase of about 179.5%[44] Financial Expenses and Investments - Financial expenses increased by 242.44% to ¥127,516,404.80 as a result of increased loans during the reporting period[23] - The company reported an investment income of ¥1,673,839.08, an increase of 80.44% compared to the previous period due to higher profits from associated companies[23] - The company recorded an investment income of ¥1,673,839.08, up from ¥927,627.85, showing improved performance in its investment activities[77] Research and Development - Research and development expenses for Q3 2019 were ¥10,252,871.00, a decrease of 54.7% from ¥22,598,433.69 in the same quarter last year[61] - Research and development expenses increased to ¥14,014,921.70, up from ¥13,831,679.53, indicating a focus on innovation[71] - Research and development expenses rose to ¥48,418,963.26, an increase of 14% from ¥42,508,653.21 in the previous period[87] Changes in Capital Structure - The capital reserve increased by 64.49% to ¥949,517,131.38 due to the conversion of bonds into shares during the reporting period[23] - Minority interests increased by 653.49% to ¥521,470,682.43 as a result of capital increases from subsidiary shareholders during the reporting period[23]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 2,714,170,240.43, representing an increase of 18.72% compared to the same period last year[28]. - The net profit attributable to shareholders of the listed company was CNY 80,011,586.86, a decrease of 25.96% year-on-year[28]. - The net profit after deducting non-recurring gains and losses was CNY 73,630,128.00, down 24.46% from the previous year[28]. - The net cash flow from operating activities was CNY 542,238,516.56, showing a significant increase of 1,355.41% compared to the same period last year[28]. - Total assets at the end of the reporting period were CNY 9,214,314,959.73, an increase of 8.29% from the end of the previous year[28]. - The net assets attributable to shareholders of the listed company were CNY 3,533,946,469.23, up 10.11% from the previous year[28]. - The basic earnings per share were CNY 0.08, a decrease of 27.27% compared to the same period last year[28]. - The diluted earnings per share were also CNY 0.08, reflecting the same percentage decrease of 27.27%[28]. - The weighted average return on net assets was 2.43%, down 1.14% from the previous year[28]. Revenue Breakdown - The company sold 620,000 tons of feed, representing a year-on-year increase of 24%[43]. - The number of pigs sold reached 407,900, up 28.68% from the previous year[43]. - The pharmaceutical business generated sales revenue of RMB 257.86 million, a year-on-year increase of 1.81%[56]. - The revenue from the pig farming business increased by 79.86% year-on-year, amounting to RMB 226.38 million[56]. - The company's feed revenue reached ¥1,309,182,100.48, an increase of 14.58% compared to the previous period[68]. - Veterinary medicine revenue surged to ¥213,221,064.47, marking a significant increase of 65.10% year-on-year[68]. - Revenue from Xinjiang region increased by 16.74% to ¥1,204,797,245.86, while revenue from outside Xinjiang rose by 19.83% to ¥1,223,295,533.02[68]. Investment and Assets - Long-term equity investments increased by 101.88% compared to the end of the previous year[45]. - Fixed assets grew by 53.61% compared to the end of the previous year[45]. - Accounts receivable rose by 128.57% compared to the end of the previous year, primarily due to government procurement sales[47]. - The total investment during the reporting period was ¥566,518,857.74, reflecting an increase of 89.72% compared to the same period last year[75]. - The company has a total of ¥6,837.44 million in mortgaged assets, primarily for bank loans[74]. - The company reported a fair value loss of ¥576,470.00 on derivative financial assets during the reporting period[79]. Dividends and Shareholder Commitments - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[12]. - The company committed to distributing at least 10% of its distributable profits in cash dividends annually over the next three years, contingent on compliance with relevant laws and regulations[120]. - The company has fulfilled its commitment regarding the lock-up period for shares acquired during the non-public offering, which is set for 36 months[120]. Corporate Governance and Compliance - The company has established a commitment to avoid any illegal occupation of funds or assets from its subsidiaries by the controlling shareholders[116]. - The company has not experienced any major litigation or arbitration matters during the reporting period[125]. - The company has not undergone any bankruptcy restructuring during the reporting period[124]. - The company has committed to maintaining its independence in management and operations as per relevant laws and regulations[120]. - The company has adhered to its commitments regarding related party transactions and will ensure compliance with market principles[116]. Risk Management and Operational Strategies - The company plans to enhance biosecurity measures to mitigate risks associated with livestock diseases, particularly African swine fever, which has impacted the industry[104]. - The company is actively working to stabilize raw material costs by establishing storage facilities in major production areas and diversifying supply channels[105]. - The company aims to improve management and feeding techniques to enhance production efficiency and reduce costs in response to price fluctuations in livestock products[108]. - The company has implemented the HACCP management system to ensure food safety and maintain product quality, addressing increasing consumer concerns[108]. Shareholder Structure and Transactions - The largest shareholder, Xinjiang Production and Construction Corps, holds 28.24% of the shares, totaling 283,929,184 shares[172]. - Beijing Rongyuan Baotong Asset Management Partnership holds 15.13% of the shares, totaling 152,133,900 shares, which are pledged[172]. - The company has not engaged in any share buyback agreements with strategic investors or general corporations[175]. - The report confirms that there are no convertible preferred shares with restored voting rights as of the reporting period[172]. Environmental and Social Responsibility - The company faced an administrative penalty of CNY 30,000 due to environmental violations related to its subsidiary, which has since implemented corrective measures[156]. - The company is actively engaged in social responsibility initiatives, including poverty alleviation efforts, although specific metrics were not detailed in the report[159]. - The company has initiated a bidding process for environmental compliance improvements at its facilities[156].

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2019-046 债券代码：128030 债券简称：天康转债 天康生物股份有限公司关于参加 2019 年新疆辖区上市公司 投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励、可持续发展等投资者所关心的问题，天康生物股份有限公司（以 下简称"公司"）定于 2019 年 7 月 26 日下午 15:00-17:30 参加由深圳证券交易 所、新疆上市公司协会联合深圳市全景网络有限公司组织开展的 2019 年新疆辖区 上市公司投资者集体接待日活动。现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net/） 或关注微信公众号：全景财经（微信号：p5w2012），参与公司本次投资者集体接 待日活动，活动时间为 2019 年 7 月 26 日（星期五）15:00 至 17:30 ...

Financial Performance - The company's operating revenue for Q1 2019 was ¥1,204,813,855.90, representing a 20.92% increase compared to ¥996,366,411.62 in the same period last year[10] - Net profit attributable to shareholders was ¥28,920,108.83, a decrease of 47.66% from ¥55,252,455.82 year-on-year[10] - The net profit after deducting non-recurring gains and losses was ¥27,206,552.91, down 49.85% from ¥54,249,567.43 in the previous year[10] - Basic earnings per share decreased by 50.00% to ¥0.03 from ¥0.06 in the previous year[10] - Operating profit, total profit, and net profit attributable to the parent company decreased by 89.42%, 89.18%, and 47.66% respectively, mainly due to the impact of swine fever on the food breeding business[25] - Net profit for the current period was ¥24,117.73, a significant decrease from ¥54,354,971.14 in the previous period[60] Cash Flow - The net cash flow from operating activities was ¥97,896,377.87, a significant improvement from a negative cash flow of ¥170,628,029.67 in the same period last year[10] - Cash flow from operating activities increased by 157.37% year-on-year, mainly due to higher revenue and reduced inventory purchases[30] - Cash flow from investing activities decreased by 165.45% year-on-year, primarily due to increased project investments in the current period[30] - Cash flow from financing activities increased by 492.93% year-on-year, reflecting a rise in loans needed for business operations[30] - Cash inflows from operating activities generated a net amount of ¥97,896,377.87, a significant recovery from a negative cash flow of ¥170,628,029.67 in the previous period[70] - Cash inflows from financing activities amounted to ¥699,779,121.20, significantly higher than ¥130,000,000.00 in the previous period, indicating a substantial increase in financing[74] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,486,857,083.03, an increase of 11.50% from ¥8,508,742,207.44 at the end of the previous year[10] - Total current assets increased to ¥5,971,303,638.20 from ¥5,857,658,521.18, reflecting a growth of approximately 1.93%[44] - Non-current assets rose significantly to ¥3,515,553,444.83 from ¥2,651,083,686.26, marking an increase of about 32.6%[44] - Total liabilities increased to ¥5,807,689,083.66 from ¥5,229,930,251.35, representing a rise of about 11.03%[46] - Long-term borrowings surged to ¥1,277,000,000.00 from ¥600,000,000.00, showing a significant increase of 112.83%[46] - The company's total liabilities increased to ¥3,680,982,801.63, compared to ¥3,118,704,637.60 in the previous period, reflecting a growth of 18%[57] Shareholder Information - The net assets attributable to shareholders were ¥3,231,009,815.42, a slight increase of 0.67% from ¥3,209,604,751.62 at the end of the previous year[10] - The top shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., held 29.47% of the shares, totaling 283,929,184 shares[15] - The company repurchased a total of 6,363,400 shares, accounting for 0.6605% of the total share capital, with a total payment of approximately 29.98 million yuan[31] Expenses - Management expenses increased by 38.18% to 73.30 million yuan due to the addition of new subsidiaries in the reporting period[24] - Financial expenses surged by 326.67% to 42.34 million yuan, primarily due to increased loans from newly added subsidiaries[24] - The company reported a tax expense of ¥4,070,370.58, up from ¥2,870,235.48 in the previous period, reflecting an increase of approximately 42%[66] Inventory and Biological Assets - The company reported a 30.44% decrease in productive biological assets, mainly due to elimination and disease impacts[27] - The company’s inventory rose to ¥206,483,003.81 from ¥188,403,931.81, reflecting an increase of approximately 9.57%[51] Research and Development - Research and development expenses for the current period were ¥12,620,993.58, slightly up from ¥12,587,270.07 in the previous period[58]

Financial Performance - The total revenue for 2018 was approximately ¥5.27 billion, representing a 13.89% increase compared to ¥4.63 billion in 2017[25] - The net profit attributable to shareholders was approximately ¥313.73 million, a decrease of 22.95% from ¥407.15 million in the previous year[25] - The basic earnings per share for 2018 was ¥0.33, down 21.43% from ¥0.42 in 2017[25] - The company's net profit attributable to shareholders decreased by 22.95% year-on-year, amounting to CNY 313.73 million[53] - The company achieved total operating revenue of CNY 5,273.03 million, a year-on-year increase of 13.89%[53] - The company reported a significant increase in investment income, rising by 311.17% due to improved profits from associated companies[48] - The company reported a total revenue of 1,488,657,266.59 CNY for Xinjiang Tiankang Huitong Agriculture Co., Ltd, with a loss of 17,898,216.93 CNY impacting overall performance[119] Cash Flow and Assets - The net cash flow from operating activities was negative at approximately ¥1.18 billion, a decline of 281.49% compared to ¥649.33 million in 2017[25] - The net cash flow from operating activities in 2018 was -¥1,178,441,646.71, a decline of 281.49% compared to a positive cash flow of ¥649,327,329.99 in 2017[93] - Total cash inflow from operating activities was ¥5,332,282,911.96 in 2018, reflecting a year-on-year increase of 12.93% from ¥4,721,642,950.29 in 2017[93] - The net increase in cash and cash equivalents was ¥283,224,132.13, a decrease of 70.18% compared to the previous year[96] - Cash and cash equivalents accounted for 25.25% of total assets at the end of 2018, down from 30.89% in 2017, a decrease of 5.64%[98] - Inventory increased significantly to ¥2,501,764,113.23, representing 29.40% of total assets, up from 15.34% in 2017, an increase of 14.06%[98] - Short-term loans rose to ¥2,675,203,032.32, accounting for 31.44% of total assets, an increase of 17.27% due to business expansion[98] Revenue Breakdown - The feed business sales revenue was CNY 2,562.07 million, up 16.45% year-on-year, accounting for 48.59% of total revenue[59] - The pharmaceutical business sales revenue reached CNY 749.86 million, a growth of 10.90% year-on-year, representing 14.22% of total revenue[59] - The revenue from pig farming increased by 69.19% year-on-year, amounting to ¥336,076,025.03[63] - The total revenue from animal husbandry was ¥854,781,986.47, with a year-on-year increase of 15.15%[63] - The company's revenue from the feed industry showed a growth of 5.7% year-on-year, with total revenue reaching ¥8,689 billion[43] Investments and Development - The company has outlined future development prospects and risk management strategies in the report[7] - The company plans to expand its "company + farmer" breeding model as pig farming scales up[54] - The company has developed multiple vaccines, including a bivalent synthetic peptide vaccine for foot-and-mouth disease, which has shown effective immune response in clinical trials[88] - The company is preparing for the export of a bivalent inactivated vaccine for small ruminant plague and goat pox, with the new veterinary drug registration expected in 2019[91] - The company has focused on improving vaccine safety and efficacy through advanced production techniques, including serum-free suspension culture methods[88] Research and Development - The company reported a total R&D investment of ¥88,192,934.83 in 2018, an increase of 28.58% compared to ¥68,587,812.65 in 2017[92] - R&D personnel increased to 203 in 2018, representing a growth of 14.69% from 177 in 2017, with R&D personnel accounting for 7.40% of the total workforce[92] - Research and development expenses for the current period amount to ¥78,650,488.60, compared to ¥53,892,824.32 in the previous period, reflecting a significant increase[148] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of ¥1.00 per 10 shares to all shareholders[8] - The total cash dividend amount for 2018 was ¥129,199,297.24, which represents 41.18% of the net profit attributable to ordinary shareholders[134] - The cash dividend amount (including tax) for 2018 was ¥99,215,797.8, accounting for 31.62% of the net profit attributable to ordinary shareholders[134] - The total distributable profit for 2018 was ¥894,331,056.12, with the cash dividend amount accounting for 100% of the profit distribution[137] - The company commits to distributing at least 10% of its distributable profits in cash dividends annually over the next three years, with potential increases if net profits remain stable[148] Risk Management - The company has identified risks related to livestock epidemics, raw material price volatility, livestock product price fluctuations, and food safety, with strategies in place to mitigate these risks[126] - The company has established a biosecurity management system across its pig farming bases to reduce the occurrence and impact of diseases[126] - The company will enhance its core competitiveness through increased investment in technology research and development[123] Corporate Governance and Compliance - The company has established a comprehensive governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring clear responsibilities and mutual checks[195] - The company emphasizes investor relations management, ensuring fair treatment of all shareholders and timely disclosure of significant information[195] - The company has not encountered any issues in the use and disclosure of raised funds[113] - The company has not faced any major litigation or arbitration matters during the reporting period[155] Market Position and Strategy - The animal vaccine market in China is projected to reach approximately 62 billion CNY by 2025, driven by increasing demand from the livestock industry[121] - The company is focusing on expanding its market share in the animal vaccine sector, particularly in pig vaccines, which hold a significant market share[121] - The company aims for a feed production and sales volume of 1.25 million tons, animal vaccine production of 1.6 billion milliliters, and a pig output of 1 million heads in 2019, with a revenue target of 6.754 billion yuan and a net profit of 413 million yuan[123]

Financial Performance - Operating revenue for the period reached ¥1,424,735,670.05, reflecting a growth of 19.06% year-on-year[8] - Net profit attributable to shareholders was ¥151,250,347.12, up by 15.59% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥150,255,378.97, an increase of 25.44% year-on-year[8] - Basic earnings per share were ¥0.16, representing a growth of 14.29% compared to the same period last year[8] - The weighted average return on equity was 4.92%, a slight increase of 0.16% from the previous year[8] Asset and Shareholder Information - Total assets increased to ¥6,784,314,014.98, a rise of 15.52% compared to the end of the previous year[8] - The total number of shareholders at the end of the reporting period was 57,643[12] - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., held 29.47% of the shares[12] Cash Flow and Receivables - Cash flow from operating activities showed a significant decline, with a net amount of ¥41,993,013.36, down 84.04% year-on-year[8] - Accounts receivable increased by 226.93% to RMB 647,271,115.58 due to year-end settlement methods in the pharmaceutical business[18] - Other receivables surged by 722.78% to RMB 226,179,340.24, primarily due to loans made to other companies[18] - The company reported a 49.03% decrease in advance receipts to RMB 129,688,984.91, as inventory sales were completed by the end of the reporting period[18] Borrowings and Financial Expenses - Short-term borrowings rose by 59.74% to RMB 1,329,000,000.00, attributed to increased loans for expanded operations[18] - Financial expenses increased by 107.85% to RMB 37,238,086.01 due to higher loan costs from expanded operations[18] Future Expectations and Plans - The company expects a net profit attributable to shareholders to decline by 30% to 0% in 2018, with an estimated range of RMB 28,500.49 to RMB 40,714.98 million[21] - The company plans to repurchase shares using its own funds, with a budget between RMB 100 million and RMB 200 million, at a price not exceeding RMB 7 per share, within a 6-month period[17] Compliance and Commitments - The company reported no significant changes in its major financial data or indicators during the reporting period[16] - There were no instances of non-compliance with external guarantees during the reporting period[23] - The company has no overdue commitments from controlling shareholders or related parties during the reporting period[20]